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Abstract 
Coronary artery disease remains a major cause of mortality. Presence of atherosclerotic plaques in the coronary artery is responsible for lu-
men stenosis which is often used as an indicator for determining the severity of coronary artery disease. However, the degree of coronary lumen 
stenosis is not often related to compromising myocardial blood flow, as most of the cardiac events that are caused by atherosclerotic plaques are 
the result of vulnerable plaques which are prone to rupture. Thus, identification of vulnerable plaques in coronary arteries has become increas-
ingly important to assist identify patients with high cardiovascular risks. Molecular imaging with use of positron emission tomography (PET) and 
single photon emission computed tomography (SPECT) has fulfilled this goal by providing functional information about plaque activity which 
enables accurate assessment of plaque stability. This review article provides an overview of diagnostic applications of molecular imaging tech-
niques in the detection of plaques in coronary arteries with PET and SPECT. New radiopharmaceuticals used in the molecular imaging of coro-
nary plaques and diagnostic applications of integrated PET/CT and PET/MRI in coronary plaques are also discussed. 
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1  Introduction  
It has become well established that plaque composition 
is a key determinant of plaque stability. High-risk 
plaques tend to be large, demonstrate positive remodel-
ling and have a large lipid core that occupies 40% or 
more of the plaque volume. These kinds of plaques are 
prone to rupture and develop intraplaque hemorrhage in 
comparison to stable plaques. Thus, the ability to non-
invasively detect and analyse these plaques at early 
stages, especially in asymptomatic and low-risk patients, 
would improve risk stratification without the need for 
more invasive procedures.[1] The development of fast CT 
scanners allows non-invasive coronary artery visualiza-
tion with high diagnostic accuracy, reliable detection of 
lumen stenosis, characterization and quantification of 
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atherosclerotic coronary plaque, and even coronary risk 
stratification.[2,3] Coronary CT angiography not only al-
lows accurate detection of coronary atherosclerotic 
plaques (Figure 1), but also enables quantitative analysis 
of plaque vessel area, lumen area, and plaque burden.[4−17] 
However, these coronary CT angiography-derived in-
dexes of plaque vulnerability demonstrated a high nega-
tive predictive value for major adverse cardiac events, 
but a low positive predictive value, thus making their 
clinical application rather limited. [18,19] 
Invasive coronary angiography is still the gold stan-
dard for the investigation of coronary lumen changes, but 
it is unable to detect atherosclerotic plaques that do not 
protrude into the lumen and does not provide information 
about plaque composition (Figure 2).[20] Intravascular 
ultrasound (IVUS) allows direct imaging of plaque and 
can provide a cross-sectional image of the entire 
atheroma and vessel wall, with important information on 
the composition of individual plaques. Advances in 
IVUS technology, such as spectral analysis of the IVUS 
backscatter radiofrequency signal have further improved 
the tissue characterization of plaques, and this technique 
is referred to as virtual histology intravascular ultrasound 
(VH-IVUS).[21] VH-IVUS spectral analysis has been 
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Figure 1.  Coronary CT angiography characterization of plaque composition. (A): calcified plaques at the left anterior de-
scending coronary artery (arrows); (B): non-calcified plaque at the right coronary artery (arrows); (C): mixed plaque at the left ante-
rior descending coronary artery (short arrow refers to calcification, while long arrow points to non-calcified component). 
 
reported to correlate well with histopathology with 
predictive accuracy of 87.1%, 87.1%, 88.3% and 
96.5% for fibrous, fibro-fatty, necrotic core, and 
dense calcium, respectively.[22,23] Furthermore, VH- 
IVUS can identify thin cap fibroatheroma and other 
plaque subtypes, and follow plaque composition 
after treatment.[24,25] However, IVUS is an invasive, 
time-consuming and expensive technique which 
demands considerable expertise, thus its use is lim-
ited to only a few clinical centers. Magnetic reso-
nance imaging (MRI) is capable of detecting plaque 
components and discriminating between lipid core, 
fibrous cap, intraplaque hemorrhage and calcifica-
tion, and can also detect macrophage-rick le-
sions.[26,27] MRI allows imaging of coronary lumen 
and plaque non-invasively without using ionizing 
radiation, with reported negative predictive value of 
88%.[28] However, coronary MR angiographic tech-
nique remains technically demanding due to limited 
spatial resolution and suboptimal signal/contrast to 
noise ratio, thus restricting its widespread accep-
tance into the clinical practice. 
 
 
Figure 2.  Limitations of invasive coronary angiography to 
demonstrate plaque components. (A): invasive coronary an-
giography shows significant lumen stenosis (arrow) at the 
proximal segment of left anterior descending coronary artery, 
but fails to demonstrate the plaque components; (B): coronary 
CT angiography clearly shows significant lumen stenosis due to 
presence of a non-calcified plaque (arrow). 
The above-mentioned invasive and non-invasive im-
aging modalities focus on providing anatomical details of 
plaque size and composition, however, molecular imag-
ing techniques such as single photon emission computed 
tomography (SPECT) and positron emission tomography 
(PET) have the potential to provide functional informa-
tion on cell biological changes which determine the risk 
of plaque rupture and furthermore, evaluate important 
determinants of plaque vulnerability by demonstrating 
specific cellular or biochemical changes. Although car-
diac SPECT and PET have been well regarded as an im-
portant diagnostic tool that provides valuable information 
about myocardial viability, perfusion and function,[29] the 
diagnostic applications of these techniques in the detec-
tion and analysis of coronary plaques are increasingly 
reported in the literature. This article aims to provide an 
overview of the clinical value of molecular imaging mo-
dalities using PET and SPECT in the detection and char-
acterization of coronary plaques. Diagnostic value of 
integrated SPECT/CT, PET/CT and PET/MRI is also 
discussed. 
2  Coronary plaque morphology 
There is increasing evidence showing that plaque mor-
phology rather than the extent of luminal stenosis deter-
mines the susceptibility of an individual to develop an 
acute coronary event. The culprit lesion (that is ruptured) 
or vulnerable plaque is defined as a “high-risk” or 
“thrombosis-prone” plaque. Morphologically, these 
plaques typically have a lipid-rich necrotic core with 
a thin fibrous cap (cap thickness of < 65 µm) infiltrated by 
macrophages. A more clinical relevant definition of a vul-
nerable plaque is a lesion that places a patient at risk for 
developing future major adverse cardiac events, including 
death or myocardial infarction.[30] The identification of 
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such plaques before they become symptomatic would en-
able prognostic stratification and facilitate primary pre-
vention (e.g., aspirin, statins, and risk factor modification). 
The concept of a vulnerable plaque or high-risk plaque 
originated from data of several studies that analyzed an-
giograms post-thrombolytic therapy or through analysis 
of serial angiographic data before and after ST-elevation 
induced acute myocardial infarction.[31−33] These studies 
showed that most infarctions were caused by lesions that 
did not have significant coronary stenosis in coronary 
lumen. It was therefore considered that disruption of mild 
and moderate coronary plaques resulted in thrombus 
formation and coronary occlusion, leading to myocardial 
infarction. Brown, et al.[34] reported that after throm-
bolytic therapy the actual size of the plaque responsible 
for the infarction was only moderate, and the remaining 
luminal narrowing was related to residual thrombus for-
mation. Due to positive (expansive or outward) vascular 
remodeling, the lumen remains relatively uncompro-
mised until the plaque has grown to a larger volume.[31] 
Thus, in most cases these plaques are clinically silent 
before the acute cardiac events occur. This emphasizes 
the importance of detecting vulnerable coronary plaques. 
However, diagnosing a vulnerable plaque which based 
on imaging assessment is imprecise to some extent, as 
the criterion of using the thickness of the fibrous cap 
alone to determine plaque vulnerability is insufficient. 
Furthermore, if presence of the lipid component indicates 
a vulnerable plaque, how much lipid-rich necrotic core 
should it possess, and how much inflammation must be 
present to make it vulnerable when initially identified?[34] 
Perhaps the most vulnerable type of coronary plaques 
might be those that are already disrupted with only small 
amounts of thrombus formation but when initially identi-
fied are not clinically symptomatic (Figure 3).[35,36] 
3  Molecular imaging of coronary plaques 
Traditionally, atherosclerotic coronary artery disease 
was only diagnosed at advanced stages by determining 
the degree of lumen stenosis or by myocardial perfusion 
assessment. However, molecular imaging modalities en-
able assessment of coronary artery disease down to the 
cellular and molecular level. Plaque inflammation is re-
garded as a reliable indicator of plaque rupture and 
thrombosis, while enzymes released by active and apop-
totic leukocytes stimulate endothelial injury, cytolysis 
and plaque disruption with subsequent thrombosis.[37,38] 
Apoptosis is considered an important indicator to predict 
plaque stability, and it has been shown to be closely 
linked to the development of a vulnerable plaque.[39] 
Apoptotic smooth muscle cell death contributes to thin-
ning of the fibrous cap, whereas apoptosis of macro-
phages and accumulation of cellular debris in the ne-
crotic core leads to expansion of the plaque necrotic core 
and positive vascular remodelling: all these features 
cause coronary plaques prone to rupture. Therefore, the 
in vivo detection of apoptosis in atherosclerotic lesions 
can assist localization of unstable plaques.[40] 
Scintigraphic techniques including SPECT and PET 
have the potential for superior functional and molecu-
lar imaging for prediction of the risk of atherosclerotic 
coronary plaque rupture. Molecular imaging provides 
diagnostic tools that target specific or nonspecific in-
flammation in coronary plaques. While such functional 
or metabolic information is superior to that provided 
by cardiac CT and MRI, SPECT and PET imaging 
techniques are limited by poor spatial and temporal 
resolution. This can be overcome with use of inte-
grated imaging techniques such as SPECT/CT and 
PET/CT or PET/MRI which are increasingly used in 
clinical practice. 
4  SPECT imaging of coronary plaques 
Technetium-99m-labelled (99mTc) radiotracers such 
as 99mTc-sestamibi and 99mTc-tetrofosmin are widely 
used in clinical practice for the investigation of myocar-
dial perfusion and viability. New 99mTc-labelled tracers 
and novel iodine-123 tracers for SPECT myocardial per-
fusion imaging are being developed recently with results 
showing high cardiac uptake and improved cardiac im-
age,[41] although further clinical studies are needed to 
verify their diagnostic value. 
99mTc-labelled tracers with SPECT have been used for 
the specific targeting of vulnerable atherosclerotic lesions 
by detecting these changes. To evaluate the feasibility of 
detection of atherosclerotic plaque in the coronary artery 
in vivo, Johnson, et al.[42] conducted a study in a 
swine model of atherosclerosis. SPECT imaging with 
99mTc-labeled with Annexin A5 was used to image the 
plaque. Histopathologic analysis showed that the coronary 
lesions in general were at an early stage and were mainly 
characterized by smooth muscle cells. Focal uptake of 
99mTc Annexin A5 was noted in 13 out of 22 coronary 
vessels in vivo. A significant correlation was found between 
the count ratio of the atherosclerotic vessels and that of con-
trol vessels. This study showed that it is possible to detect 
atherosclerotic plaque apoptosis in vivo in the coronary ar-
tery with similar dimensions to the human heart. 
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Figure 3.  Vulnerable plaque. In the upper panel, the middle figure shows a presumed vulnerable plaque, a thin-capped atheroma with 
a large/necrotic core, and a thin fibrous cap infiltrated by inflammatory cells, which is thought to be the immediate precursor of sympto-
matic thrombosed plaque (upper right). However, as shown in the lower panel, a “vulnerable plaque” might not be an easy diagnosis to 
make with one or more invasive/noninvasive techniques. The true precursor to a symptomatic thrombosed plaque might depend on such 
factors as the exact cap thickness, size of the lipid/necrotic core, inflammatory cell volume, thrombogenicity of the blood, and others. 
Reprint with permission from reference [35]. 
 
Although 99mTc SPECT is able to assess atheroscle-
rotic coronary lesions in experimental studies,[39,41] most 
of the clinical studies using SPECT for imaging vulner-
able plaques focus on the investigation of patients with 
carotid plaques.[43−45] Increased uptake of radioisotopes 
was reported in culprit coronary lesions when compared 
to the normal arteries, which did not demonstrate tracer 
accumulation. Furthermore, 99mTc SPECT has been 
shown to be able to detect the presence of inflammation 
in carotid plaques, which plays an important role in pro-
moting plaque rupture.[46,47] Compared to coronary CT 
angiography, integrated SPECT/CT technique has been 
reported to provide a complimentary role in the diagnos-
tic evaluation of patients with suspected coronary artery 
disease, with improved specificity and positive predictive 
value without significant change in sensitivity and nega-
tive predictive value.[48−51] However, most of the current 
studies using integrated SPECT/CT focus on myocardial 
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perfusion imaging, investigation of the integrated imag-
ing modality for identification of culprit coronary plaque 
is limited, thus, further studies are warranted. 
Despite these promising reports, the important applica-
tion of nuclear cardiac imaging lies in the utilization of 
PET in imaging vulnerable plaque as SPECT is limited 
by its poor spatial resolution in imaging coronary arteries 
and coronary lesions. Cardiac SPECT imaging has been 
used for myocardial perfusion and viability for many 
years and is a well-established and the most commonly 
used imaging modality in these areas.[28] 
5  PET imaging of coronary plaques 
5.1  Commonly used radiopharmaceutical-Fluoro 
deoxyglucose PET 
Cardiac PET has higher spatial and contrast resolution 
than SPECT, thus it allows a more conspicuous identifi-
cation of regional differences in radiotracer uptake and 
thus increasing the sensitivity for detection of athero-
sclerotic changes in the coronary arteries. Fluorodeoxy-
glucose (FDG) with PET is a molecular imaging tech-
nique that is highly sensitive to metabolically active 
processes using glucose as a fuel. After being labeled 
with 18F, the resultant 18F-FDG is taken up into metab-
olically active but is not metabolized and thereby 
accumulates in atherosclerotic plaques. In oncology, 
18F-FDG uptake by tumors makes PET the gold standard 
for the detection of metastatic disease.[52] In cardiology, 
18F-FDG PET is routinely performed to estimate myo-
cardial glucose consumption, in compromised myocar-
dium, uptake of FDG indicates viability and likely posi-
tive response to myocardial revascularization.[53] In addi-
tion to the widespread use of 18F-FDG PET for screen-
ing and staging of cancers, 18F-FDG PET is the most 
sensitive modality for visualizing inflammation, because 
18F-FDG shows accumulation in inflammatory cells in 
which glucose metabolism is activated.[54] 
Arterial 18F-FDG PET imaging has been increasingly 
used as a biomarker to investigate the metabolic activity 
of atherosclerosis.[39] The first data on 18F-FDG PET 
imaging in human atherosclerotic plaque inflammation 
was reported in patients with carotid plaques.[55] The 
study demonstrated the ability of 18F-FDG PET imaging 
to identify inflammatory activity in unstable carotid 
plaques in patients undergoing carotid endarterectomy 
compared to the contralateral asymptomatic artery. 
18F-FDG was taken up by atherosclerotic plaque and 
selectively accumulated in macrophage-rich areas. Later 
reports by others confirmed the clinical value of 
18F-FDG -PET in detecting vulnerable atherosclerotic 
coronary plaques.[56−59] 
Dunphy, et al.[56] reported the feasibility of imaging 
proximal coronary plaques using 18F-FDG PET with 
results showing greater FDG accumulation in arterial 
wall due to atherosclerotic plaques (inflammatory 
changes) than adjacent blood pool activity. Williams and 
Kolodny in their retrospective study consisting of 60 
lymphoma patients found focal FDG uptake along the 
coronary artery tree in 15 of them.[57] The concordance 
between focal FDG uptake in coronary arteries and 
coronary calcification was 55%, and the concordance 
between coronary artery FDG uptake and history of 
coronary artery disease was 77%. Their results provided 
early evidence of the possibility of using 18F-FDG PET 
to monitor sites of coronary plaque formation, however 
large and prospective studies are needed to determine the 
diagnostic value of this technique. Wykrzykowska, et al.[59] 
evaluated the potential value of 18F-FDG PET to image 
inflammation in coronary arteries in 32 cancer patients 
who underwent coronary catheterization. After special 
dietary intervention suppressing myocardial glucose up-
take, 18F-FDG uptake was identified in 15 patients in 1 
or more coronary segments with atherosclerosis con-
firmed by invasive coronary angiography. 
In addition to detecting the above changes associated 
with atherosclerotic plaques, 18F-FDG PET has been 
shown to monitor response to therapeutic interventions, 
according to several recently published studies.[60−65] In-
flammation plays a key role in the progression and de-
stabilization of atherosclerotic plaque. 18F-FDG PET has 
been confirmed to be a promising tool for visualizing 
inflammation of atherosclerotic plaque, thus, anti- 
inflammatory action by medications could be demon-
strated through modification of vascular FDG uptake. 
The authors of a prospective study assessed effects of a 
3-month statin supplementation on vascular FDG uptake 
in 43 patients with high baseline FDG uptake in aorta 
and carotid arteries.[64] Half of the patients received sim-
vastatin (5-20mg/day) while the other half was dietary 
group receiving dietary management only. The mean 
standardized uptake value of FDG at the end of the study 
period was found to decrease by 10% in the simvas-
tatin-treated group when compared to the baseline. 
Changes that were demonstrated on FDG-PET repre-
sented decreased inflammation in the atherosclerotic 
plaque.[64] These early findings are confirmed by a recent 
multicenter study using FDG-PET to monitor the statin 
therapy.[65] Tawakol, et al.[65] investigated whether 
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high-dose statin treatment resulted in greater reductions in 
plaque inflammation than low-dose statins using FDG-PET. 
Sixty-eight patients were randomized to atorvastatin 10 vs. 
80 mg and followed up at 4 and 12 weeks with FDG-PET 
imaging of the aorta and carotid arteries. Results showed 
that reduction in plaque activity was apparent as early as 4 
weeks, although inflammation (FDG uptake) in these arter-
ies was significantly reduced from baseline with atovastatin 
80 mg at 12 weeks, but not with atorvastatin 10 mg. This 
first multicenter trial further confirms the ability of PET 
imaging as a tool to detect changes in vascular inflammation 
early in the course of treatment. 
5.2  New radiopharmaceuticals in cardiac PET 
Although 18F-FDG is a convenient and widely used 
radiopharmaceutical, investigation of more specific tar-
geting agents for the detection of plaque inflammation 
and identification of plaque rupture has been increasingly 
reported in the literature.[66−68] 18F-labeled mannose 
(2-deoxy-2-[18F] fluoro-D-mannose, 18F-FDM) repre-
sents a subset of macrophages and it may offer a con-
venient target for imaging of vascular inflammation us-
ing appropriately labeled 18F-FDM. Tahara, et al.[69] in 
their recent report compared the uptake of 18F-FDM 
with 18F-FDG in animal experiments, and their results 
showed comparably high specific uptake of both tracers 
in the abdominal aortas and aortic arches of atheroscle-
rotic animals, according to both in vivo and ex vivo im-
ages. Furthermore, increased expression of mannose re-
ceptor-bearing macrophages in unstable plaques and spe-
cific binding of FDM to the mannose receptor was ob-
served in the study, which indicates the potential value of 
use of 18F-FDM in high-risk plaques, although clinical 
studies are required to confirm these findings. 
Quantifying the amount of coronary artery calcium 
with cardiac CT scan has been widely accepted as a reli-
able non-invasive technique for screening risk of future 
cardiac events.[17,70] Despite clinical value for predicting 
future cardiac events, cardiac CT does not accurately 
assess plaque inflammatory state and the degree of mo-
lecular calcification which reflects plaque stability.[71,72] 
18F-sodium fluoride (18F-NaF) is a new radiopharma-
ceutical which has been proposed to assess the accuracy 
in detecting the process of molecular calcification in the 
vasculature.[73] Preliminary studies have demonstrated 
high correlation between the cardiovascular risk factor 
and the degree of molecular calcification in the heart and 
aorta,[73,74] as well as additional information about plaque 
physiology with use of 18F-NaF, although more prospec-
tive studies are required to verify these findings. 
In addition to the above-mentioned radiopharmaceuti-
cals, many other tracers have been investigated and 
tested for imaging of atherosclerotic plaques including 
11C-choline,[75] 18F-galacto-RGD,[76] 11C-acetate,[77] 
and 11C-PK11195.[78] Since 11C-PK11195 specifically 
binds to macrophages through translocator proteins that 
are highly expressed on activated macrophages, it may be 
more specific for imaging of atherosclerosis than 
18F-FDG.[79] Despite promising results reported, clinical 
trials on patients are needed to prove their clinical effi-
cacy of imaging atherosclerosis. 
In summary, PET imaging of atherosclerosis contrib-
utes significantly to identify individuals at high-risk ear-
lier in the disease processes by detecting the changes at 
the early stage of disease. It may also prove to be useful 
in determining the biological responses to certain thera-
peutic treatment and intervention. The principal strength 
of PET imaging lies in its excellent sensitivity, good 
depth of penetration, and quantitative capabilities.[79] 
However, there are some issues to be resolved in PET 
imaging of coronary lesions: the small size of athero-
sclerotic lesions and their closeness with blood, and the 
continuous respiratory and cardiac movements during the 
acquisition of the images.[80−82] Furthermore, there is a 
lack of correlation between PET imaging of atheroscle-
rotic plaques and pathological findings and clinical con-
firmation of adverse cardiac events. 
6  Integrated PET/CT imaging of coronary 
plaques 
The integration of nuclear medicine with multislice 
CT such as PET/CT and SPECT/CT provides a unique 
opportunity to delineate cardiovascular abnormalities 
and their physiological consequences in a single setting. 
For the assessment of the patient with known or sus-
pected coronary artery disease, it allows detection and 
quantitative analysis of the plaque burden, vascular re-
activity and endothelial health, identification of 
flow-limiting coronary lesions, and assessment of myo-
cardial perfusion and viability. Thus, by revealing the 
burden of anatomic coronary artery disease and its 
physiologic significance, integrated imaging can pro-
vide unique information for risk assessment and guid-
ance of management of coronary artery disease.[83] As 
discussed in previous sections, SPECT/CT mainly deals 
with myocardial perfusion imaging in the current lit-
erature,[48−51] thus, this section will focus on PET/CT in 
imaging analysis of coronary plaques. 
The feasibility of using PET/CT in the detection of 
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soft plaque in the coronary artery was demonstrated in 
a case report.[58] Fused PET/CT images identified and 
localized areas of increased FDG uptake in the proxi-
mal segments of the left coronary artery with noncal-
cified plaque, which was related to inflamed athero-
sclerotic lesions. The increased clinical availability of 
PET/CT scanners enables non-invasive detection of 
high-risk atherosclerotic plaques. Menezes, et al.[84] 
retrospectively reviewed PET/CT images in 50 pa-
tients who had at least 4 examinations over a period of 
5 years. Results showed that areas of focal arterial 
18F-FDG uptake are transient, and there is no rela-
tionship between arterial 18F-FDG uptake and calcifi-
cation. As there is considerable evidence indicating 
that 18F-FDG is a biomarker for plaque instabil-
ity,[55,85,86] their results provide insight into the natural 
history of arterial lesions, which could translate into 
important clinical implications. 
Although 18F-FDG is useful as a marker of vascular 
inflammation, 18F-FDG PET may not be able to 
demonstrate the plaque rupture due to complex re-
cruitment process of multiple cell types that are in-
volved in the high-risk plaque. Therefore, there re-
mains necessity for development of other tracers that 
can selectively target inflammation in plaques and that 
is able to identify an atherosclerotic plaque at risk for 
rupture, thus enabling earlier intervention and possibly 
improving outcomes. 18F-NaF-PET/CT imaging is 
considered a useful tool to detect molecular calcifica-
tion at earlier stages of the atherosclerotic process as 
microcalcification has been implicated in plaque rup-
ture.[73,74,87] The authors of a study published in 
2014 elegantly demonstrated that compared to 
18F-FDG, 18F-NaF-PET/CT represents the first non-
invasive imaging modality to identify and localize 
ruptured and high-risk coronary plaques.[88] In this 
prospective clinical trial, 40 patients with myocardial 
infarction and 40 patients with stable angina under-
went 18F-FDG and 18F-NaF-PET/CT, and invasive 
coronary angiography. 18F-NaF activity in the culprit 
coronary plaques was 34% higher than the myocar-
dium activity (maximum tissue-to-background ratio 
1.66 [1.40-2.25] vs. 1.24 [1.06-1.38], P < 0.001) 
(Figure 4). In contrast, coronary 18F-FDG uptake was 
essentially indistinguishable from patch myocardial 
uptake in 22 patients and increased uptake was ob-
served in the culprit vessels of 6 patients.[88] This 
study shows for the first time that ruptured or 
high-risk plaque of rupture can be identified by non-
invasive imaging modality, thus 18F-NaF-PET/CT has 
the potential to alter management of patients with sta-
ble and unstable coronary artery disease. 
Nahrendorf et al. presented their preclinical data on im-
aging vascular cell adhesion molecule (VCAM)-1 by inte-
grated PET/CT imaging in murine atherosclerosis.[89] The 
expression of VCAM-1 is increased at lesion-prone sites 
and in atherosclerotic plaques, which is expressed by en-
dothelial as well as smooth muscle cells and macro-
phages.[89,90] To validate in vivo PET/CT data, the authors 
correlated 18F-4V (the 4V, a synthetic peptide, was la-
beled with 18F for PET imaging of VCAM-1) uptake to 
expression of VCAM-1 in atherosclerotic mice receiving a 
high-cholesterol diet as well as wild type murine models 
of myocardial infarction and heart transplant rejection. The 
authors reported that 18F-4V accumulated in atheroscle-
rotic plaques, mostly in the endothelium overlying aortic 
plaques, which is detected by in vivo and ex vivo PET/CT 
imaging (Figure 5). Furthermore, PET/CT showed in-
creased uptake of 18F-4V in myocardium after myocardial 
infarction and during transplant rejection. Their results 
demonstrate an important advance in molecular imaging of 
vascular inflammation that brings a step closer to the real-
ity of PET/CT imaging in humans.[89] 
7  Integrated PET/MRI imaging of coro-
nary plaques 
The availability of PET/MRI systems may dramati-
cally facilitate the translation of promising PET imaging 
into the clinic for atherosclerotic plaque imaging owing 
to the superior soft tissue contrast of MRI imaging.[91,92] 
Millon, et al.[93] in their recent experimental study 
showed the feasibility of using combined PET/MRI for 
assessment of changes in the inflammation of athero-
sclerotic plaques. 18F-FDG PET seems to be more sensi-
tive than contrast-enhanced MRI to detect early changes 
in plaque inflammation. 
Although CT can provide high-resolution anatomi-
cal images during PET/CT scanners, misalignments 
between PET and CT data are common since the two 
imaging modalities are not acquired simultaneously. In 
the recently developed PET/MRI scanners, PET and 
MR data are acquired simultaneously so that informa-
tion obtained with MRI can be used to improve analy-
sis of information content of PET images. Motion 
corrected PET/MRI which was proposed in a recent 
study solved the issue of misalignments encountered 
in PET/CT since all PET data are reconstructed within 
the same reference phase, which allows accurate spa-
tial registration between PET and MR data.[94] This 
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technique has been shown to improve visualization 
and detection of coronary plaques. Multimodal imag-
ing of plaques such as PET/MRI could be an ideal ap-
plication since combination of the imaging methods 
works synergistically to maximize diagnostic potential 
of each imaging modality and enables the detection 
and quantification of the burden of the extent of calci-
fied and non-calcified plaques, quantification of vas-
cular reactivity and endothelial health, identification 
of flow-limiting coronary stenosis, and potential iden-
tification of high-risk plaques in coronary arteries.[95] 
Currently, PET/MRI is limited to preclinical cardiac 
imaging with focus on animal experiments, thus, more 
studies with further technical advances are expected to 
prove its clinical value in cardiac imaging. 
8  Nanoparticle-targeted imaging of coro-
nary plaques 
The advancements of nanotechnology have led to several 
inventions of novel nanoparticle-targeted contrast agents for 
various imaging modalities. This achievement may also 
significantly contribute towards detecting and characterizing 
the vulnerable atherosclerotic plaques. Indeed, several stud-
ies have shown that nanoparticle-targeted imaging enables 
to increase the sensitivity value as compared with those 
‘traditional’ invasive procedures.[96−98] A number of 
nanoparticle contrast agents have been comprehensively 
studied for molecular imaging of atherosclerotic-related 
biomarkers, and most of the works have involved iron oxide 
nanoparticle which has been assessed by MRI.[99−101] 
 
 
Figure 4.  Focal 18F-fluoride and 18F-fluorodeoxyglucose uptake in patients with myocardial infarction and stable angina. Patient 
with acute ST-segment elevation myocardial infarction with (A): proximal occlusion (red arrow) of the left anterior descending artery on 
invasive coronary angiography and (B): intense focal 18F-fluoride (18F-NaF, tissue-to-background ratios, culprit 2.27 vs. reference segment 
1.09 [108% increase]) uptake (yellow-red) at the site of the culprit plaque (red arrow) on the combined positron emission and computed to-
mogram (PET-CT). Corresponding 18F-fluorodeoxyglucose PET-CT image (C): showing no uptake at the site of the culprit plaque (18F-FDG, 
tissue-to-background ratios, 1.63 versus reference segment 1.91 [15% decrease]). Note the significant myocardial uptake overlapping with 
the coronary artery (yellow arrow) and uptake within the oesophagus (blue arrow). Patient with anterior non-ST-segment elevation myocar-
dial infarction with (D): culprit (red arrow; left anterior descending artery) and bystander non-culprit (white arrow; circumflex artery) lesions 
on invasive coronary angiography that were both stented during the index admission. Only the culprit lesion had increased 18F-NaF uptake 
(18F-NaF, tissue-to-background ratios, culprit 2.03 vs. reference segment 1.08 [88% increase]) on PET-CT (E): after percutaneous coronary 
intervention. Corresponding 18F-fluorodeoxyglucose(18F-FDG), PET-CT showing no uptake either at the culprit (18F-FDG, tis-
sue-to-background ratios, culprit 1.62 vs. reference segment 1.49 [9% increase]) or the bystander stented lesion. Note intense uptake within 
the ascending aorta (F). Reprint with permission from reference [88]. 
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Figure 5.  18F-4V imaging in myocardial infarction and transplant rejection. (A): PET-CT shows strong signal in the infarcted left ventricu-
lar wall. (B): Infarcted myocardium shows delayed CT hyperenhancement after iodine (arrows). (C): Autoradiography of myocardial ring. (D): 
%IDGT in the infarct. (E): VCAM-1 mRNA in infarct tissue. (F, G): PET-CT of a heart transplanted heterotopically into the abdominal cavity. 
The rejected allograft (arrowheads) shows high uptake of 18F-4V. (H, I): Autoradiography of graft and orthotopic recipient heart. (J): Uptake of 
18F-4V in rejected allografts. (K): VCAM-1 mRNA levels in control heart tissue and rejected cardiac allografts. *P < 0.05. MI = myocardial in-
farction, VCAM-vascular cell adhesion muscle, IDGT-injected dose/gram tissue. Reprint with permission from reference [89]. 
 
Iron oxide nanoparticle is a biocompatible superpara-
magnetic material that has been widely used as MRI con-
trast agent for the identification of atherosclerotic 
plaques in clinical setting.[102] However, to be a clinically 
approved MRI contrast agent, iron oxide nanoparticle 
shall be coated with dextran (known as dextran-coated 
iron oxide; DIO) which is biocompatible and biodegrad-
able, making it suitable for clinical application.[103] 
This DIO nanoparticle is commonly applied for con-
trast-enhanced T1 and T2-weighted MRI scans. Never-
theless, due to the difficulty in fabricating a uniform di-
mension of DIO nanoparticle, Tu, et al.[104] introduced a 
new synthetic method by sulfating DIO with sulfur tri-
oxide pyridine complex, and produced the sulfated DIO 
(SDIO) nanoparticle. Their preclinical T2-weighted MRI 
(with gradient echo sequence) data showed that at 4-hour 
post injection, SDIO provides a significantly higher con-
trast ratio than those of DIO. This finding suggests that 
SDIO has superior contrast enhancing quality because it 
is more preferably to be accumulated at the site of 
atherosclerotic plaque. Majmudar, et al.[105] in their re-
cent study used polymetric nanoparticles consisting of 
zirconium-89 radiolabelled dextra nanoparticles (DNP) 
in integrated PET/MRI imaging of atherosclerotic 
plaques. PET/MRI has been shown to be able to detect 
inflammatory cells in atheroma with radioiso-
tope-labelled DNP, and track response in the arterial in-
tima after anti-inflammatory therapy (Figure 6). Clinical 
translation of this molecular imaging technique could 
assist identification of vulnerable plaques at high risk for 
complications and assessment of the treatment outcomes 
in atherosclerotic plaques. 
Finally, with the advent of integrated imaging modal-
ity, Nahrendorf et al have successfully developed a novel 
trimodality nanoparticle contrast agent that can directly 
detect the high level of macrophages in atherosclerotic 
plaques.[106] This fascinating discovery would be of great 
value for being utilized in PET/CT and PET/MR scans, 
and therefore numerous molecular imaging-based out-
comes on early detection of vulnerable atherosclerotic 
plaques are expected to be revealed in the near future. 
9  Summary and concluding remarks 
Imaging research of coronary artery disease has 
mainly focused on myocardial perfusion imaging and 
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Figure 6.  Positron emission tomography/magnetic resonance image (PET/MRI) and gene expression analysis of siRNA treated 
ApoE−/− mice. (A): Representative PET/MRI of control siRNA (siCON) and siCCR2-treated ApoE−/− mice. Inset: MRI frame at the level of 
the aortic valve. (B): PET target-to-background ratio in ApoE−/− mice treated with control siRNA (siCON) vs siCCR2 (n = 5 per group). 
Data are presented as mean ± SEM, *P < 0.05. (C): Heat map of genes in aortic roots (n = 4 per group). Each row of the heat map repre-
sents a gene, whereas each column represents an experimental treatment group (labeled at the bottom). The color scale represents the level of 
gene expression, with red indicating an increase in gene expression and blue indicating a decrease in gene expression. ApoE: apolipoprotein; 
Arg1 indicates arginase 1; CCR2: C-C chemokine receptor type 2; IL: interleukin; siRNA: short-interfering RNA; siCON: si control; MPO: 
myeloperoxidase; TBR: target-to-background ratio; TGF: transforming growth factor; TNF: tumor necrosis factor; and VCAM: vascular cell 
adhesion molecule 1. Reprint with permission from reference [105]. 
 
morphological analysis of coronary lumen stenosis or 
obstruction, however, the great challenge at present is 
to differentiate stable plaques from vulnerable ones, 
thus, identifying patients at high risk for developing 
acute cardiac events before clinical syndromes appear, 
therefore, achieving the goal of reducing cardiac mor-
tality. Molecular imaging with use of radiopharmaceu-
ticals by SPECT and PET techniques has the potential 
to identify vulnerable or high-risk plaques. This re-
view provides an overview of the diagnostic applica-
tions of cardiac SPECT and PET in the detection of 
coronary plaques. In particular, cardiac PET including 
integrated PET/CT and PET/MRI has been shown to 
identify atherosclerotic changes at the early stage of 
coronary artery disease by accurately determining the 
plaque activity. With more research being conducted 
in the near future, it is expected that research findings 
will improve risk stratification of patients with coro-
nary artery disease. More studies are needed to inves-
tigate whether increased uptake of radioisotopes cor-
relates with a future risk of cardiac events or plaque 
rupture, or whether molecular imaging can be used to 
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guide patient therapy and management. 
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